Cogent Biosciences, Inc. (COGT) Stock

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is led by CEO Andrew R. Robbins, employs 258 people, headquartered in Waltham, US, publicly traded since 2018.

Cogent Biosciences, Inc. (COGT) stock trades at $31.21 with a market capitalization of $5.42B. The stock is valued at a negative price-to-earnings (P/E) ratio of -13.36, reflecting a net loss over the last twelve months, price-to-book of 9.92, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $13.78 and $43.73, and currently trades 28.6% below its 52-week high.

On profitability, Cogent Biosciences, Inc. generates a return on equity (ROE) of -72.57% (negative, reflecting a net loss), return on capital employed of -50.19%.

Cogent Biosciences, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Cogent Biosciences, Inc. reported revenue of $6.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-329.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-376.0M.

Borrowings stand at $253.0M, cash from operations was $-264.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -62.9% over five years, and was -51.7% in the most recent year.

The share price itself has compounded at 29.2% a year over five years, 39.8% over three, 368.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cogent Biosciences, Inc. (COGT) — frequently asked questions